Magnetic Resonance Fingerprinting for Brain Cancer

Overseen By Chaitra A Badve, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Case Comprehensive Cancer Center

Disqualifiers: Pregnancy, Pacemaker, Claustrophobia, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: Varies based on individual treatment plans

172 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new imaging technique called magnetic resonance fingerprinting (MRF) to diagnose and assess brain tumors more effectively. It aims to provide detailed information about tumor tissue and compare this method with other imaging tests and clinical data to evaluate its accuracy. The trial involves two groups: individuals recently diagnosed with brain tumors and those with previously treated tumors that might be recurring. Suitable candidates for this trial are those diagnosed with a brain tumor who can undergo several follow-up scans. As an unphased trial, this study offers a unique opportunity to advance diagnostic techniques for brain tumors.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that this magnetic resonance fingerprinting technique is safe for brain tumor assessment?

Research has shown that Magnetic Resonance Fingerprinting (MRF) is safe in many medical settings. Studies have found it can differentiate between various brain tumors and other conditions without harming patients. No reports have specifically linked negative effects to MRF. As a type of MRI scan, MRF shares a similar safety record with standard MRI procedures, which are generally well-tolerated. This suggests MRF is likely safe for people, as it does not involve surgery or radiation. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about Magnetic Resonance Fingerprinting (MRF) because it offers a new way to visualize brain tumors. Unlike standard MRI scans, MRF provides a more detailed and quantitative fingerprint of tissues, which can help differentiate between tumor types and monitor changes over time. This technique could potentially lead to earlier detection of tumor recurrence and more personalized treatment plans, enhancing the effectiveness of standard therapies like surgery, radiation, and chemotherapy. By offering precise imaging insights, MRF holds promise in improving outcomes for patients with brain cancer.

What evidence suggests that magnetic resonance fingerprinting is effective for brain cancer?

Research has shown that Magnetic Resonance Fingerprinting (MRF) effectively creates detailed images of brain tumors. It quickly measures important features like T1 and T2, aiding in tumor identification and understanding. Studies have found that MRF accurately maps tumor tissue, crucial for diagnosis and assessing treatment effectiveness. Participants in this trial will undergo MRF scans to enhance the detection and monitoring of brain tumors, offering a more detailed view compared to traditional MRI methods. This technology promises to improve the detection and monitoring of brain tumors. ^{2 6 7 8 9}

Who Is on the Research Team?

Chaitra A Badve, MD

Principal Investigator

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center

Are You a Good Fit for This Trial?

This trial is for adults with a new or previously treated brain tumor who can give informed consent themselves or through a legal representative. It's not for those with non-MRI safe implants, metallic foreign objects in their body, severe claustrophobia, pregnant women, prisoners, vulnerable populations, non-English speakers, or minors.

Inclusion Criteria

I can understand and am willing to sign the consent form, or I have someone legally authorized to do so on my behalf.

I have brain metastases and can have scans at specified times after targeted brain radiation.

I have a brain tumor that was either found at the start or has shown signs of growth on scans.

Exclusion Criteria

Patients with contraindications for MRI due to embedded foreign metallic objects such as bullets, shrapnel, metalwork fragments, or other metallic material

Implanted medical device not described above that is not MRI-compatible

I am under 18 years old.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Initial Imaging and Diagnosis

Participants undergo volumetric MRI study with contrast and 3D-MRF acquisition for surgical planning or clinical diagnosis

1-2 weeks

Treatment

Participants receive standard of care surgery, radiation, and chemotherapy

Varies based on individual treatment plans

Follow-up Imaging

Follow-up MRF scans are performed to visualize recurrence and differentiate post-treatment changes from tumor recurrence

Ongoing as determined by clinical care

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months

What Are the Treatments Tested in This Trial?

Interventions

• Magnetic Resonance Fingerprinting

Trial Overview The study tests Magnetic Resonance Fingerprinting (MRF), an advanced MR imaging technique that quickly scans and provides detailed tissue data. This will be compared to standard imaging and clinical information to check its accuracy in diagnosing and assessing brain tumors.

How Is the Trial Designed?

Group I: Treated tumors with possible recurrence Experimental Treatment 1 Intervention

Participants with treated brain tumors with possible recurrence will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be added to the repeat MRI studies as determined appropriate by the referring physician/primary care team.

Group II: Newly Diagnosed Brain Tumors Experimental Treatment 1 Intervention

Participants with newly diagnosed brain tumors will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be performed to visualize recurrence.

Who Is Running the Clinical Trial?

Case Comprehensive Cancer Center

Lead Sponsor

Trials

472

Recruited

33,400+

Published Research Related to This Trial

Magnetic resonance fingerprinting (MRF) is a promising imaging technique that allows for the simultaneous measurement of multiple tissue properties, leading to the creation of accurate and reproducible quantitative maps.

The review highlights the expanding applications of MRF in various fields, including neuroimaging, prostate, liver, kidney, and cardiac imaging, indicating its potential for broad clinical use.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Magnetic Resonance Fingerprinting: A Review of Clinical Applications. Gaur, S., Panda, A., Fajardo, JE., et al.[2023]

The study successfully demonstrated the feasibility of using MR fingerprinting (MRF) for 3D whole-brain T1 and T2 mapping on a 0.55 T MRI system, achieving high spatial resolution and a quick acquisition time of 8.5 minutes.

T1 and T2 values obtained from MRF were highly correlated with standard measurements, showing strong accuracy and precision (less than 5%) even in the lower signal-to-noise ratio environment of 0.55 T.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Feasibility of MR fingerprinting using a high-performance 0.55 T MRI system. Campbell-Washburn, AE., Jiang, Y., Körzdörfer, G., et al.[2022]

Magnetic Resonance Fingerprinting (MRF) demonstrated a high predictability for identifying tumor regions and grading in gliomas, achieving 88.9% accuracy for low-grade gliomas and 75% for high-grade gliomas among 17 patients studied.

While both MRF and PET imaging provide valuable quantitative data on gliomas, they reflect different biological mechanisms, indicating that they may complement each other rather than replace one another in clinical assessments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Evaluation of Gliomas with Magnetic Resonance Fingerprinting with PET Correlation-A Comparative Study. Marik, W., Cardoso, PL., Springer, E., et al.[2023]

Magnetic resonance fingerprinting (MRF) can quickly and effectively differentiate between tumor tissue and normal white matter in pediatric brain tumor patients, with a median scan time of just 11 minutes.

MRF successfully distinguishes between low-grade and high-grade tumors based on T1 and T2 relaxation times, indicating its potential as a valuable diagnostic tool for assessing tumor characteristics in children and young adults.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Magnetic Resonance Fingerprinting to Characterize Childhood and Young Adult Brain Tumors. de Blank, P., Badve, C., Gold, DR., et al.[2020]

Magnetic Resonance Fingerprinting (MRF) is a cutting-edge imaging technique that allows for the simultaneous and efficient measurement of multiple tissue properties, which could lead to more accurate and objective diagnoses.

MRF has shown promise in various applications, including brain, prostate, liver, and cardiac imaging, as well as in assessing microvascular properties, indicating its potential to enhance patient monitoring and the development of imaging biomarkers.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Magnetic Resonance Fingerprinting-An Overview. Panda, A., Mehta, BB., Coppo, S., et al.[2020]

Magnetic resonance fingerprinting (MRF) is a cutting-edge MRI technology that can simultaneously generate multiple high-resolution property maps, such as T1, T2, and ADC measurements, which are useful for various clinical applications including brain tumors and prostate cancer.

Despite its rapid development and potential, MRF still faces challenges that need to be addressed to fully establish it as a reliable quantitative imaging biomarker in clinical practice.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Magnetic resonance fingerprinting: an overview. Tippareddy, C., Zhao, W., Sunshine, JL., et al.[2021]

MR fingerprinting (MRF) is a reliable technique for assessing tissue relaxation times, showing a strong correlation between measured and reference values in a phantom study, which supports its accuracy for clinical use.

In a study of 20 patients with meningiomas, MRF revealed significantly longer T1 and T2 relaxation times in meningiomas compared to surrounding brain structures, indicating its potential for quantitative assessment of these tumors in clinical practice.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Whole-brain 3D MR fingerprinting brain imaging: clinical validation and feasibility to patients with meningioma. Mostardeiro, TR., Panda, A., Witte, RJ., et al.[2021]

Tailored magnetic resonance fingerprinting (TMRF) can rapidly provide quantitative maps (T1, T2) and qualitative images in pediatric brain tumor patients, potentially saving about 2 minutes in imaging time.

In a study of five pediatric patients, TMRF-derived T2 weighted images showed strong correlation with standard imaging methods, indicating its effectiveness in differentiating between healthy and pathological tissues.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Tailored magnetic resonance fingerprinting of post-operative pediatric brain tumor patients. Poojar, P., Qian, E., Jin, Z., et al.[2023]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC5352493/

MR Fingerprinting of Adult Brain Tumors: Initial Experience MR fingerprinting allows rapid simultaneous T1 and T2 measurement in brain tumors and surrounding tissues. MR fingerprinting–based relaxometry can identify ...

2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC8507535/

Current Applications and Future Development of Magnetic ... This review summarises recent studies detecting and characterising tumours using MRF, with a focus on brain tumours, prostate cancers, and abdominal/pelvic ...

3. clinicaltrials.gov clinicaltrials.gov/study/NCT02956291

Multi-Parametric Quantitative MR Imaging in Evaluation of ... The purpose of the research study is to test new methods that could improve diagnosis and assessment of brain tumors. One of these methods is a new MR (magnetic ...

4. sciencedirect.com sciencedirect.com/science/article/abs/pii/S0899707123001687

Tailored magnetic resonance fingerprinting of post- ... Malignant tumors tend to proliferate and may regrow after being resected. MRI is ideal for neuro-oncology, especially for tumor localization and follow-ups.

5. aapm.onlinelibrary.wiley.com aapm.onlinelibrary.wiley.com/doi/10.1002/mp.15254

Technical overview of magnetic resonance fingerprinting and ... Magnetic resonance fingerprinting to characterize childhood and young adult brain tumors. Pediatr Neurosurg. 2019; 54(5): 310-318. 10.1159 ...

6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC5984038/

Magnetic Resonance Fingerprinting-An Overview - PMC Clinically MRF has been used to differentiate between various brain tumors, separate prostate cancer from normal prostatic tissue and characterize liver ...

7. sciencedirect.com sciencedirect.com/science/article/pii/S1053811921005140

Streamlined magnetic resonance fingerprinting: Fast whole ... This study aims to introduce a novel streamlined magnetic-resonance fingerprinting (sMRF) framework based on a single-shot echo-planar imaging (EPI) sequence.

8. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC8833555/

MR Fingerprinting—A Radiogenomic Marker for Diffuse Gliomas The purpose of this study was to evaluate the use of MR Fingerprinting as a radiogenomic marker to differentiate gliomas according to the ...

9. clinicaltrials.gov clinicaltrials.gov/study/NCT06455189

Magnetic Resonance Fingerprinting Guided Extended ... The goal of this study is to determine if MR fingerprinting, new way of acquiring MRI images, can help identify the extent of tumor spread in the brain, better ...